NYSEAMERICAN:ARMPArmata Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Armata Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.94 -0.05 (-1.25 %) (As of 07/9/2020 04:00 PM ET) Add Compare Share Today's Range$3.92Now: $3.94▼$4.0450-Day Range N/A52-Week Range$2.52Now: $3.94▼$6.92Volume10,000 shsAverage Volume113,248 shsMarket Capitalization$43.05 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingArmata Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.33, Armata Pharmaceuticals has a potential upside of 86.1% from its current price of $3.94.Amount of Analyst CoverageArmata Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesArmata Pharmaceuticals has received 31 “outperform” votes. (Add your “outperform” vote.)Underperform VotesArmata Pharmaceuticals has received 21 “underperform” votes. (Add your “underperform” vote.)Community SentimentArmata Pharmaceuticals has received 59.62% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Armata Pharmaceuticals and other stocks. Vote “Outperform” if you believe ARMP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARMP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldArmata Pharmaceuticals does not currently pay a dividend.Dividend GrowthArmata Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Armata Pharmaceuticals insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.30 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorHealth Technology Current SymbolNYSEAMERICAN:ARMP Previous Symbol CUSIPN/A CIKN/A WebN/A Phone(310) 655-2928Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares10,927,000Market Cap$43.05 million Next Earnings Date8/12/2020 (Estimated) OptionableNot Optionable AMEX:ARMP Rates by TradingView Receive ARMP News and Ratings via Email Sign-up to receive the latest news and ratings for ARMP and its competitors with MarketBeat's FREE daily newsletter. Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Armata Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Armata Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Armata Pharmaceuticals. When is Armata Pharmaceuticals' next earnings date? Armata Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Armata Pharmaceuticals. How were Armata Pharmaceuticals' earnings last quarter? Armata Pharmaceuticals Inc (NYSEAMERICAN:ARMP) released its earnings results on Thursday, May, 14th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.19. View Armata Pharmaceuticals' earnings history. What price target have analysts set for ARMP? 3 Wall Street analysts have issued 1 year price targets for Armata Pharmaceuticals' stock. Their forecasts range from $5.00 to $9.00. On average, they anticipate Armata Pharmaceuticals' share price to reach $7.33 in the next twelve months. This suggests a possible upside of 86.1% from the stock's current price. View analysts' price targets for Armata Pharmaceuticals. What are Wall Street analysts saying about Armata Pharmaceuticals stock? Here are some recent quotes from research analysts about Armata Pharmaceuticals stock: 1. According to Zacks Investment Research, "Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company's principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California. " (5/25/2020) 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy and $7 price target. The sole contributor to our valuation, at this point is AB-SA01, with a projected 15% chance of success with $415 million in peak sales off of a 2024 launch. Overall, we believe that our projected chance of success could be considered conservative based on the efficacy and safety profile, to date, in very sick patients, and continues to highlight the valuation disconnect, in our belief. We do not include projections for the P. aeruginosa program, and would look to reevaluate based on visibility on the path forward." (8/15/2019) Has Armata Pharmaceuticals been receiving favorable news coverage? Media stories about ARMP stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Armata Pharmaceuticals earned a news sentiment score of -2.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Armata Pharmaceuticals. Who are some of Armata Pharmaceuticals' key competitors? Some companies that are related to Armata Pharmaceuticals include AquaBounty Technologies (AQB), Ibio (IBIO), Oncolytics Biotech (ONC), Navidea Biopharmaceuticals (NAVB), Cocrystal Pharma (COCP), Circassia Pharmaceuticals (CIR), Orgenesis (ORGS), Helix Biopharma (HBP), Ampio Pharmaceuticals (AMPE), Novoheart (NVH), Biopharmx (BPMX), Omega Diagnostics Group (ORPH), Orthocell (OCC), Cohbar (CWBR) and Cynata Therapeutics (CYP). View all competitors. What other stocks do shareholders of Armata Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Armata Pharmaceuticals investors own include Vaxart (VXRT), Crispr Therapeutics (CRSP), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Altimmune (ALT), Advanced Micro Devices (AMD), Amarin (AMRN), Aytu Bioscience (AYTU), Nabriva Therapeutics (NBRV) and Protalix Biotherapeutics (PLX). Who are Armata Pharmaceuticals' key executives? Armata Pharmaceuticals' management team includes the following people: Todd R. Patrick, Chief Executive Officer & DirectorBrian C. Varnum, President & Chief Development OfficerDuane A. Morris, Vice President-OperationsSteven Robert Martin, Chief Financial Officer & Head-Media Contacts What is Armata Pharmaceuticals' stock symbol? Armata Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ARMP." How do I buy shares of Armata Pharmaceuticals? Shares of ARMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Armata Pharmaceuticals' stock price today? One share of ARMP stock can currently be purchased for approximately $3.94. How big of a company is Armata Pharmaceuticals? Armata Pharmaceuticals has a market capitalization of $43.05 million. How can I contact Armata Pharmaceuticals? The company can be reached via phone at (310) 655-2928. This page was last updated on 7/9/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
